Eye Journal

23/02/2026

[Eye Open] New research explores whether patients with macular disease are comfortable with artificial intelligence being used to guide treatment decisions.

In a survey of 181 participants, respondents were asked to rank different scenarios involving AI or human decision making, varying error rates, turnaround times and whether results were double checked. The findings show that patients are broadly accepting of AI in the assessment of retinal images. What mattered most was accuracy and having a checking mechanism in place, rather than whether the initial decision was made by a human or an AI system.

The study highlights that as AI becomes more integrated into macular clinics, patient priorities should remain central. Clear standards around accuracy and robust oversight will be key to building confidence and supporting safe adoption.

Read in full here: https://www.nature.com/articles/s44440-025-00011-7

11/02/2026

New study of 105 eyes shows a 23G trocar sleeve adapter can dramatically speed up silicone oil injection during vitreoretinal surgery.
Injection time fell from 259s to 90s for Densiron 68, and from 774s to 153s for Silicone 5000, both p < 0.0001. That is a threefold to fivefold reduction.
Only three disconnections occurred. No major complications.
A simple device change may substantially cut operative time. Randomised studies are now needed to confirm these findings.

https://www.nature.com/articles/s41433-026-04279-6

05/02/2026

Changes in hyperreflective choroidal foci over time may predict treatment response and risk of pachychoroid macular atrophy in chronic central serous chorioretinopathy, supporting their role as prognostic biomarkers.
Read now : https://www.nature.com/articles/s41433-026-04277-8

29/01/2026

Vigilance matters: in a 9-year UK study of 664 phthisical eyes, unsuspected intraocular malignancy occurred in 0.75% of cases, all after evisceration. Even with low risk, careful assessment and histopathology are essential.

https://www.nature.com/articles/s41433-025-04224-z

26/01/2026

New research published in Eye Open describes a rare but important complication following DSAEK.

This case report shows how severe corneal melt can appear clinically as a descemetocele even when Descemet’s membrane has already been removed. The authors identify a “pre-descemetocele”, supported by the pre-Descemet’s layer, with evidence of stromal remodelling following treatment.

The findings deepen our understanding of corneal anatomy and have practical implications for diagnosing and managing corneal melt after endothelial keratoplasty.

Read the full article in Eye Open: https://www.nature.com/articles/s44440-025-00008-2

20/01/2026

** NEW IN EYE OPEN **
Diabetic macular oedema lacks a single, standard way to classify disease. That makes diagnosis, treatment decisions, and trial design harder.

This review proposes the C-METRICAL system. It combines clinical assessment, OCT, and angiography, and includes morphology, biomarkers, retinopathy severity, and key systemic comorbidities.

A unified approach could improve consistency in trials and everyday practice, however, further studies are needed to test its real world value.

https://www.nature.com/articles/s44440-025-00009-1

13/01/2026

NEW in EYE OPEN: New research shows promising long-term visual improvements for patients with significant vision loss from retinal conditions following Excimer-Laser-Multiple-Light-Redirection (Excimer-MLR).
In this small study, treated eyes showed sustained gains in visual acuity and contrast sensitivity over up to two years, with most patients gaining 15 or more ETDRS letters, alongside improved retinal sensitivity and reduced central scotomas. The corneal procedure was safe, required no customisation or visual training, and worked synergistically with existing retinal therapies, highlighting its potential as a novel approach to neuroadaptive vision restoration.

https://www.nature.com/articles/s44440-025-00010-8

12/01/2026

🚨 NEW! 🚨 New phase 1 data suggest a potential breakthrough for Stargardt disease type 1, a condition with no approved treatments.
In the GARDian1 trial, a single subretinal dose of OCU410ST was well tolerated and slowed retinal atrophy by around 50 percent versus untreated eyes, while treated eyes gained an average of six ETDRS letters over 12 months.
These first-in-human results point to a genotype-agnostic approach that could help preserve central vision and change the outlook for patients.


https://www.nature.com/articles/s41433-025-04202-5

09/01/2026

New real world data over three years shows Hydrus Microstent and triple iStent inject W deliver similar outcomes when combined with surgery for open angle glaucoma. Both lowered IOP by about 2 to 3 mmHg, cut drops by more than one medication on average, left over half of patients medication free, and showed good safety. Device choice can reasonably come down to surgeon preference and individual patient factors.

https://www.nature.com/articles/s41433-025-04196-0

22/12/2025

SPOTTED: One of Santa’s reindeer observed transiting the macula seen in an en face OCT retinal image 🦌

Many thanks to the team at the Southampton Eye Unit for this festive cover image. 🎄

https://www.nature.com/eye/volumes/39/issues/18

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the si...

11/12/2025

From evidence to recommendations, from global to local: Our new editorial introduces ophthalmologists to GRADE EtD & Adolopment frameworks for adapting trustworthy guidelines to context.

Part of the 'Research Methodology for the Ophthalmologist' online collection

https://www.nature.com/articles/s41433-025-04139-9

09/12/2025

New research using the TriNetX network shows that people with ulcerative colitis who also have ocular inflammatory disease face higher risks of intestinal complications, extraintestinal morbidity, rheumatologic disease and cardiovascular events. No increased risk was seen for colorectal cancer or mortality

https://www.nature.com/articles/s41433-025-04151-z